Notice of Results
16 March 2009 - 6:01PM
UK Regulatory
TIDMLMT
RNS Number : 8657O
Lombard Medical Technologies PLC
16 March 2009
Press Information
Lombard Medical Technologies PLC
Notification of Results
London, UK, 16 March 2009 - Lombard Medical Technologies PLC (AIM: LMT), the
specialist medical device company, will be announcing its preliminary results
for the year ended 31 December 2008 on Wednesday, 1 April 2009.
An analyst briefing will be held at 09.30am on 1 April 2009 at the offices of
Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2.
Enquiries:
+--------------------------------------------------+----------------------+
| Lombard Medical Technologies PLC | Tel: +44 (0) 1235 |
| Simon Neathercoat, Non-executive Chairman | 750 800 |
| Brian Howlett, Chief Executive Officer | |
| Tim Hall, Finance Director | |
+--------------------------------------------------+----------------------+
| | |
+--------------------------------------------------+----------------------+
| Financial Dynamics | Tel: +44 (0) 20 7831 |
| Jonathan Birt / Susan Quigley | 3113 |
+--------------------------------------------------+----------------------+
| | |
+--------------------------------------------------+----------------------+
| Nomura Code Securities Limited | Tel: +44 (0) 20 7776 |
| Juliet Thompson / Richard Potts | 1200 |
+--------------------------------------------------+----------------------+
Notes to editors
About Lombard Medical
Lombard Medical Technologies PLC is a medical devices group developing stent
grafts and other medical products for use in the treatment of vascular disease.
The Company's lead product, Aorfix(TM), is an endovascular stent graft for the
treatment of abdominal aortic aneurysms (AAAs), a balloon-like enlargement of
the aorta which, if untreated, may rupture and cause death. Approximately 1.7
million people have AAAs in the US where it is the 13th largest cause of death.
The market for endovascular stent grafts for the treatment of AAA is currently
worth over $600 million and is expected to grow to around a $1 billion by 2010.
Aorfix(TM) is currently being commercialised in the EU, with a pivotal clinical
trial ongoing in the USA.
The Company's Polymer Coatings Division has developed a novel hydrophilic
surface treatment to reduce friction on catheters called GlideMax(TM), which is
available for licensing, and is using its polymer coating technology in a number
of research collaborations developing novel products for the $5 billion
drug-eluting stent market.
The Company is headquartered in Oxfordshire, with operations in Yorkshire,
Ayrshire and Boston, USA.
Further background on the Company can be found at www.lombardmedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORKGGMFVFVGLZM
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Lombard Med.Tec (London Stock Exchange): 0 recent articles
More Lombard Medical Tech News Articles